Natixis Advisors, L.P. Vaxcyte, Inc. Transaction History
Natixis Advisors, L.P.
- $53.5 Billion
- Q4 2024
A detailed history of Natixis Advisors, L.P. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 15,537 shares of PCVX stock, worth $1.31 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,537
Previous 22,697
31.55%
Holding current value
$1.31 Million
Previous $2.59 Million
50.96%
% of portfolio
0.0%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding PCVX
# of Institutions
350Shares Held
132MCall Options Held
577KPut Options Held
310K-
Vanguard Group Inc Valley Forge, PA12MShares$1 Billion0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$888 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$835 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$730 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$522 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.98B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...